MedPath

Empowering Hispanic Patients' Lung Cancer Screening Uptake (Empower Latinx)

Not Applicable
Recruiting
Conditions
Lung Cancer
Interventions
Other: Usual Care
Behavioral: Brief Patient Education
Behavioral: Patient education
Behavioral: Referral to financial navigation resources
Behavioral: Patient Reminders
Behavioral: Provider Reminders
Registration Number
NCT06225414
Lead Sponsor
University of California, Irvine
Brief Summary

The Hispanic/Latinx community (hereafter Hispanic) is the country's second-largest racial/ethnic group, accounting for 19.1% of the total population. However, they remain one of the most underserved populations with suboptimal access to healthcare and screening services due to low income, lack of health insurance, perceived discrimination, language barriers, and limited health literacy. Lung cancer is the leading cause of cancer related mortality with 1.8 million annual deaths worldwide, with Hispanic patients known to have lower survival rates compared with non-Hispanic whites. Lung cancer screening (LCS) with low dose computed tomography (LDCT) decreases this mortality rate of lung cancer by 20%. Yet many Latinx patients who are eligible for lung cancer screening are still falling through the cracks which prevents patients the ability to detect lung cancer early. This study will test and compare the effect of a multi-level intervention on ordering LDCT within 4 months after patient enrollment to those in an Enhanced Usual Care. Our proposed intervention includes:

* Primary care provider notifications of patients' LCS eligibility;

* Patients' education;

* Patients' referral to financial navigation resources;

* Patients' reminder to discuss LCS during primary care provider (PCP) visit.

Detailed Description

Not available

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
60
Inclusion Criteria
  • Aged 50- 80 years of age.
  • Be able to speak English and Spanish
  • Must have a scheduled appointment with their Primary Care Providers within next one to three months.
  • The Scheduled PCP appointment is at any of the 4 University of California Irvine Health (UCI Health) primary care clinics in Orange County including two UCI federally qualified health centers
  • History of 20-pack year smoking history ( based on survey self-report)
  • Current smoker or a former smoker who has quit smoking within the last 15 years (based on survey self-report)
Exclusion Criteria
  • Prior history of lung cancer
  • Chest CT for any reason in the last 12 months based on self-report and UCI EMR
  • History of Alzheimer's disease or dementia

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Arm A: Enhanced Usual CareUsual CareUsual Care + Brief Educational Material
Arm A: Enhanced Usual CareBrief Patient EducationUsual Care + Brief Educational Material
Arm B: Empower LatinxPatient education* PCP notifications of patients' LCS eligibility (addressing provider time constraints and barrier in identifying eligible patients); * Patients' education (addressing knowledge barriers); * Patients' referral to financial navigation resources (addressing health-related social risks) * Patients' reminder to discuss LCS during PCP visit.
Arm B: Empower LatinxUsual Care* PCP notifications of patients' LCS eligibility (addressing provider time constraints and barrier in identifying eligible patients); * Patients' education (addressing knowledge barriers); * Patients' referral to financial navigation resources (addressing health-related social risks) * Patients' reminder to discuss LCS during PCP visit.
Arm B: Empower LatinxReferral to financial navigation resources* PCP notifications of patients' LCS eligibility (addressing provider time constraints and barrier in identifying eligible patients); * Patients' education (addressing knowledge barriers); * Patients' referral to financial navigation resources (addressing health-related social risks) * Patients' reminder to discuss LCS during PCP visit.
Arm B: Empower LatinxPatient Reminders* PCP notifications of patients' LCS eligibility (addressing provider time constraints and barrier in identifying eligible patients); * Patients' education (addressing knowledge barriers); * Patients' referral to financial navigation resources (addressing health-related social risks) * Patients' reminder to discuss LCS during PCP visit.
Arm B: Empower LatinxProvider Reminders* PCP notifications of patients' LCS eligibility (addressing provider time constraints and barrier in identifying eligible patients); * Patients' education (addressing knowledge barriers); * Patients' referral to financial navigation resources (addressing health-related social risks) * Patients' reminder to discuss LCS during PCP visit.
Primary Outcome Measures
NameTimeMethod
Number of participants with order of Low-dose CT (LDCT) for lung cancer screening (LCS)Within 4 months of randomization
Secondary Outcome Measures
NameTimeMethod
Number of Participants who received LDCT for LCSWithin 4 months of randomization
Patients' perceived severity of lung cancerBaseline and 4 months after randomization

5-items about the health consequences and severity of lung cancer will be used. The responses for each item will be based on a 5-point likert scale. A sum score will be calculated based on responses to all items. Score will range between 5-25. Higher score= higher perceived benefits.

Patients' self-efficacy of lung cancer screeningBaseline and 4 months after randomization

10-item self-efficacy for lung cancer screening questionnaire will be used. 9 of these items were developed by Carter Harris et al (Cancer Nurs, 2018). The responses for each item will be based on a 5-point likert scale. A sum score will be calculated based on responses to all 9 validated item. Score will range between 9 and 45. Higher score= higher self-efficacy. An additional score including all 10 items will also be calculated.

Patients' knowledge about lung cancer screeningBaseline and 4 months after randomization

9 questions adopted and modified from Volk R et al (PMID: 24518006) will be used. Responses will be based on true, false, unsure. Sum of correctly responded questions will be calculated. Higher score= higher knowledge.

Number of Participants with the documented discussion of lung cancer screening with their providers in the electronic medical recordWithin 4 months of randomization
Patients' perceived barriers of lung cancer screeningBaseline and 4 months after randomization

19-item perceived barriers of lung cancer questionnaire will be used. 17 of these items were developed by Carter Harris et al (Cancer Nurs, 2018). The responses for each item will be based on a 5-point likert scale. A sum score will be calculated based on responses to all 17 validated items. Score will range between 17 and 85. Higher score= higher perceived barriers. An additional score including all 19 items will also be calculated.

Patients' perceived risk of lung cancerBaseline and 4 months after randomization

3-item perceived risk of lung cancer questionnaire developed by Carter Harris et al (Cancer Nurs, 2018) will be used. The responses for each item will be based on a 5-point likert scale. A sum score will be calculated based on responses to all 3 item. Score will range between 3 and 15. Higher score= higher perceived risk.

Patients' perceived benefits of lung cancer screeningBaseline and 4 months after randomization

6-item perceived benefit of lung cancer questionnaire developed by Carter Harris et al (Cancer Nurs, 2018) will be used. The responses for each item will be based on a 5-point likert scale. A sum score will be calculated based on responses to all items. Score will range between 6-30. Higher score= higher perceived benefits.

Trial Locations

Locations (4)

UCI Health Family Health Center - Anaheim

🇺🇸

Anaheim, California, United States

UCI Health SeniorHealth Center -Pavillion 4

🇺🇸

Orange, California, United States

UCI Medical Center, Pavilion 3

🇺🇸

Orange, California, United States

UCI Health Family Health Center - Santa Ana

🇺🇸

Santa Ana, California, United States

© Copyright 2025. All Rights Reserved by MedPath